Background/Aims: Despite the cystic fibrosis gene product, the cystic fibrosis transmembrane conductance regulator, being widely expressed throughout the kidney, there is no clearly defined renal phenotype in patients with cystic fibrosis. As patients with cystic fibrosis survive longer progressive pancreatic destruction may lead to abnormal glucose tolerance and diabetes mellitus, which in the kidney may be associated with the characteristic changes of nodular glomerulosclerosis. Methods: The adult cystic fibrosis service at the Alfred hospital consists of a cohort of 200 patients. We describe 3 cystic fibrosis patients with impaired renal function who had renal biopsies performed as part of their diagnostic work-up. All patients had fasting plasma glucose levels, oral glucose tolerance tests and measurements of HbA1c performed to assess for the presence of cystic fibrosis-related diabetes mellitus. Results: The renal biopsies of all 3 patients showed histological changes characteristic of diabetic nephropathy. In all cases described characteristic Kimmelstiel-Wilson nodules were present. However, in all 3 patients the presence of impaired glucose tolerance and diabetes mellitus was excluded using standard biochemical diagnostic criteria. Conclusion: We describe 3 adult CF patients, who on renal biopsy had histological evidence of nodular glomerulosclerosis in the absence of abnormal glucose metabolism. We speculate that the pro-inflammatory cytokine profile, typical of cystic fibrosis, predisposes to the lesions described.

1.
Tsui L, Buchwald M, Barker D, Barker D, Braman JC, Knowlton R, Schumm JW, Eiberg H, Mohr J, Kennedy D, Plavsic N, et al: Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985;239:1054–1057.
2.
Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, Smith AE, Welsh MJ: Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991;253:202–205.
3.
Kulczycki LL, Kostuch M, Bellanti JA: A clinical perspective of cystic fibrosis and new genetic findings: Relationship of CFTR mutations to genotype-phenotype manifestations. Am J Med Genet 2003;116A:262–267.
4.
Moran AM, Doherty L, Wang X, Thomas W: Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998;133:10–17.
5.
Milla CE, Warwick WJ, Moran A: Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162:891–895.
6.
Lanng S, Thorsteinson B, Nerup J, Koch C: Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992;151:684–687.
7.
Kimmelstiel P, Wilson C: Intracapillary lesions in the glomeruli of the kidney. Am J Pathol 1936;12:83–97.
8.
Bell ET: Renal vascular disease in diabetes mellitus. Diabetes 1953;2:376–389.
9.
Herzenberg AM, Holden JK, Singh S, Magil AB: Idiopathic nodular glomerulosclerosis. Am J Kidney Dis 1999;34:560–564.
10.
Preud’homme J-L, Aucouturier P, Touchard G, Striker L, Khamlichi AA, Rocca A, Denoroy L, Cogne M: Monoclonal immunoglobulin deposition disease (Randall type): Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994;46:965–972.
11.
Sanders PW, Herrera G, Kirk KA, Old CW, Galla JH: Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991;64:527–537.
12.
Alpers CE, Magil AB, Biava CG: Fibrillary glomerulonephritis. Prog Reprod Urin Tract Pathol 1989;1:197–212.
13.
McCarty NA: Permeation through the CFTR chloride channel. J Exp Biol 2000;203:1947–1962.
14.
Alpers CE, Biava CG: Idiopathic lobular glomerulonephritis (nodular mesangial sclerosis): A distinct diagnostic entity. Clin Nephrol 1989;32:68–74.
15.
Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D’Agati VD: Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol 2002;33:826–835.
16.
Brownlee M, Cerami A, Vlassara H: Advanced glcosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315–1321.
17.
Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, Ibrahim SA: Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging and uremia. Diabetes 1992;41:36–41.
18.
Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949–955.
19.
Kent MJC, Light ND, Bailey AJ: Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. Biochem J 1985;225:745–752.
20.
Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, et al: Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997;46:1881–1887.
21.
Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K: Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999;10:822–832.
22.
Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889–901.
23.
Andersson KB, Sletten K, Berntzen HB, Dale I, Brandtzaeg P, Jellum E, Fagerhol MK: The leucocyte L1 protein: Identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1998;28:241–245.
24.
Foell D, Seeliger S, Vogl T, Koch H-G, Maschek H, Harms E, Sorg C, Roth J: Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003;58:613–617.
25.
Lal MA, Brismar H, Eklof A, Aperia A: Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002;61:2006–2014.
26.
Anderson MM, Requena JR, Crowley JR, Thorper SR, Heineche JW: The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103–113.
27.
Linsdell P, Hanrahan JW: Glutathione permeability of CFTR. Am J Physiol 1998;275:C323–C326.
28.
Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D’Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656–1666.
29.
Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and ageing complications. Proc Natl Acad Sci USA 1992;89:12043–12047.
30.
Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C: Glucose tolerance in patients with cystic fibrosis: Five year prospective study. BMJ 1995;311:655–659.
31.
Cucinotta D, De Luca F, Scoglio R, Lombardo F, Sferlazzas C, Di Benedetto A, Magazzu G, Raimndo G, Arrigo T: Factors affecting diabetes mellitus onset in cystic fibrosis: Evidence from a 10-year follow-up study. Acta Paediatr 1999;88:389–393.
32.
Scanlin TF, Glick MC: Terminal glycosylation in cystic fibrosis. Biochim Biophys Acta 1999;1455:241–253.
33.
Hill WG, Harper GS, Rozaklis T, Boucher RC, Hopwood JJ: Organ-specific over-sulfation of glycosaminoglycans and altered extracellular matrix in a mouse model of cystic fibrosis. Biochem Mol Med 1997;62:113–122.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.